Home    中文  
 
  • Search
  • lucene Search
  • Citation
  • Fig/Tab
  • Adv Search
Just Accepted  |  Current Issue  |  Archive  |  Featured Articles  |  Most Read  |  Most Download  |  Most Cited

Chinese Journal of Critical Care Medicine(Electronic Edition) ›› 2024, Vol. 17 ›› Issue (04): 301-306. doi: 10.3877/cma.j.issn.1674-6880.2024.04.005

• Original Article • Previous Articles    

Predictive efficacy of secretory leukocyte protease inhibitor in severe pneumonia patients with non-invasive ventilation

Lie Zhang1,(), Yihe Yan2, Jieyu Du3   

  1. 1. Department of Neurology, Shaoxing 7th People's Hospital, Shaoxing 312000, China
    2. Department of Critical Care Medicine, Shaoxing People's Hospital, Shaoxing 312000, China
    3. Department of General Medicine, Shaoxing 7th People's Hospital, Shaoxing 312000, China
  • Received:2024-05-31 Online:2024-08-31 Published:2024-09-29
  • Contact: Lie Zhang

Abstract:

Objective

To analyze the predictive efficacy of lower respiratory secretory leukocyte protease inhibitor (SLPI) on the 28-day survival of severe pneumonia (SP) patients with respiratory failure (RF) treated by non-invasive ventilation (NIV).

Methods

Eighty-two SP patients with RF treated by NIV from Shaoxing 7th People's Hospital and Shaoxing People's Hospital between April 2021 and April 2023 were divided into a death group (25 cases) and a survival group (57 cases) according to their 28-day survival. The general clinical data and SLPI levels of lower respiratory tract secretions were compared between the two groups. A logistic regression model was used to analyze the influencing factors on the 28-day survival of SP patients with RF treated by NIV, and the predictive efficacy of each influencing factor on the 28-day survival of SP patients with RF was analyzed by a receiver operating characteristic (ROC) curve.

Results

Compared with the survival group, patients in the death group were older [62 (43, 75) years vs. 64 (52, 78) years, Z = 3.044, P = 0.003], the proportion of severe RF [26.32% (15/57) vs. 52.00% (13/25), χ2 = 5.098, P = 0.024], pathogen species ≥ 2 [35.09% (20/57) vs. 60.00% (15/25), χ2 = 4.408, P = 0.036] and acute physiology and chronic health evaluation Ⅱ (APACHE Ⅱ) score [17 (10, 21) vs. 20 (13, 23), Z = 3.140, P = 0.002] were significantly increased, and the oxygenation index [(325 ± 60) mmHg vs. (284 ± 32) mmHg, t = 3.284, P = 0.002] and SLPI levels [(843 ± 102) μg/L vs. (735 ± 93) μg/L, t = 4.524, P < 0.001] were obviously decreased. Logistic regression model analysis showed that the age [odds ratio (OR) = 2.240, 95% confidence interval (CI) (1.340, 3.745), P = 0.002], pathogen species ≥ 2 [OR = 2.804, 95%CI (1.447, 5.434), P = 0.002] and APACHEⅡ score [OR = 2.598, 95%CI (1.268, 5.324), P = 0.009] were risk factors for 28-day survival in SP patients with RF treated by NIV, and the oxygenation index [OR = 0.582, 95%CI (0.383, 0.883), P = 0.011] and SLPI [OR = 0.507, 95%CI (0.281, 0.917), P = 0.019] were the protective factors. The ROC curve showed that the best cutoff value for SLPI to predict 28-day survival in SP patients with RF treated by NIV was 806.50 μg/L, with the area under the curve (AUC) of 0.788 [95%CI (0.684, 0.871), P < 0.001], and its AUC was much higher than that of age, pathogen species ≥ 2, APACHEⅡ score and oxygenation index (Z = 1.989, P = 0.047; Z = 2.629, P = 0.009; Z = 2.231, P = 0.026; Z = 2.438, P = 0.015).

Conclusion

The SLPI of lower respiratory tract secretions is a protective factor for 28-day survival in SP patients with RF treated by NIV, and is effective in predicting their survival.

Key words: Non-invasive ventilator, Severe pneumonia, Respiratory failure, Secretory leukocyte protease inhibitor

京ICP 备07035254号-20
Copyright © Chinese Journal of Critical Care Medicine(Electronic Edition), All Rights Reserved.
Tel: 0571-87236467 E-mail: zhwzzyxzz@126.com
Powered by Beijing Magtech Co. Ltd